The Effect of Terlipressin on Intesitnal Function in Septic Shock Patients
Launched by LIU ZIMENG · Dec 2, 2014
Trial Information
Current as of May 09, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • septic shock
- Exclusion Criteria:
- • shock due to other reasons
- • diagnosited intesitinal ischemia
About Liu Zimeng
Liu Zimeng is a dedicated clinical trial sponsor committed to advancing medical research and innovation. With a focus on enhancing patient outcomes through rigorous study design and execution, Liu Zimeng collaborates with leading healthcare professionals and institutions to conduct high-quality clinical trials across various therapeutic areas. The organization prioritizes ethical standards and regulatory compliance while fostering an environment of scientific integrity and transparency. Through its strategic partnerships and commitment to excellence, Liu Zimeng aims to contribute meaningful insights to the medical community and improve treatment options for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Guangzhou, Guangdong, China
Patients applied
Trial Officials
liu zimeng, master
Principal Investigator
the first affiliated hospital of SUMS
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials